Thymine derivatives and quinazoline-dione derivatives for the inhibition of hsp27
US-2018207160-A1 · Jul 26, 2018 · US
US9102630B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9102630-B2 |
| Application number | US-201414206540-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 12, 2014 |
| Priority date | Mar 29, 2010 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided is a crystal of a salt of the compound represented by formula (I), which is excellent in its solubility in water. In particular, also provided is a crystal of hydrochloride, hydrobromate, sulfate, nitrate, p-toluenesulfonate or methanesulfonate of the compound represented by formula (I).
Opening claim text (preview).
What is claimed is: 1. A method of treating rheumatoid arthritis, inflammatory, intestinal diseases, systemic lupus erythematosus, disseminated or multiple sclerosis, Sjogren's syndromes, asthma, psoriasis, allergy, diabetes (mellitus), cardiovascular diseases, arterial sclerosis, restenosis, tumor hyperplasia, tumor metastasis, or graft rejection, comprising administering to a subject in need thereof an effective amount of a the compound represented by formula (I): or a pharmaceu…
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.